Plain-English translation of NCT06787911 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Thyroid Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether donafenib combined with sintilimab (a type of immunotherapy medication) can help shrink locally advanced thyroid cancer before surgery. Patients receive this two-drug combination as a "neoadjuvant" treatment — meaning it's given before surgery to make the cancer easier to remove. The trial will look at how well the medications work and whether they are safe.
Some people with advanced thyroid cancer have tumors that are difficult or risky to remove completely with surgery alone. Researchers hope that giving this medication combination before surgery will shrink the cancer and make surgery safer and more successful.
You likely qualify if…
You likely don't qualify if…
You will receive the two medications (donafenib and sintilimab) as neoadjuvant therapy before your surgery. After completing this treatment, if you are eligible, you will have surgery to remove the thyroid cancer. Throughout the study, your doctors will monitor you with blood tests, imaging scans, and other exams to see how well the treatment is working and to watch for any side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China